Jun Watanabe

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor

Daisuke Honma, Osamu Kanno, Jun Watanabe et al. · Cancer Science · 2017 · 139 citations · Full text

Histone Modifications, Histone H3, Epigenetic Change +27

Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy

Yu Kanemaru, Manabu Natsumeda, Masayasu Okada et al. · Acta Neuropathologica Communications · 2019 · 66 citations · Full text

High Detection Rate of <i>MYD88</i> Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas

Jun Watanabe, Manabu Natsumeda, Masayasu Okada et al. · JCO Precision Oncology · 2019 · 55 citations

POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity

Aileen Patricia Szczepanski, Natsumi Tsuboyama, Jun Watanabe et al. · Science Advances · 2022 · 46 citations · Full text

High Incidence of Deep Vein Thrombosis in the Perioperative Period of Neurosurgical Patients

Manabu Natsumeda, Takeo Uzuka, Jun Watanabe et al. · World Neurosurgery · 2017 · 40 citations

Thrombosis, Pulmonary Embolism, Venous Thrombosis +10